Dell, VMware shares surge on spinoff report - San Francisco News
by Maria Thomas
Updated Jun 24, 2020
According to a Wall Street Journal report, Dell, which owns 81 per cent of software virtualization company VMware, is looking to either sell its holding or buy the remaining stake.
Dell shares were over 8 per cent high at $52.89 each.
VMware shares were also seen 4.5 per cent higher at $156.06, keeping its market value at around $67 billion, reports The Street.
"Dell Technologies Inc. is examining options including a spinoff for its roughly $50 billion stake in VMware Inc. as the PC maker seeks to boost the value of its shares," the WSJ report said on Tuesday.
"Dell recently kicked off a process to explore the possibility of unloading the stake or taking other steps that could include buying the rest of the cloud-software giant, according to people familiar with the matter".
In 2004, EMC (now Dell EMC) acquired VMware with $625 million in cash.
Dell owns 801 of the Palo Alto, California-based company, which it got as part of the deal when it bought EMC for $67 billion in 2015.
VMware in 2018 announced $2 billion investment in India over the next five years towards expanding its facilities, increase headcount and ramp up research and development activities.
Key to VMware's success has been innovation in products and strategic partnership with major players like Amazon, IBM, HP, Microsoft and Google.
Related Articles
- Optical Illusion Brain Test: If you have Sharp Eyes Find the Number 442 in 20 Secs
- London-based firm Nothing to release its Phone (2)
- Covid will continue to cause mini-waves, not become seasonal yet: Scientists
- Hackers offering crypto accounts for as low as $30 on darknet
- Reddit's new feature to allow users to share its content on other platforms
- Surgical masks can help kids fight respiratory infections: Study
- LinkedIn's new AI feature to write messages to hiring team
- Microsoft introduces Xbox Game Pass' new Friend Referral programme
- Disbursed over Rs 31 cr in claims to delivery partners in FY22-23: Swiggy
- India emerging as favourable destination for clinical trials: Report